Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 7
2010 13
2011 13
2012 17
2013 13
2014 23
2015 19
2016 10
2017 5
2018 10
2019 11
2020 10
2021 17
2022 20
2023 17
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J, Arnold DM, Grossbard E, Mayer J, Treliński J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovtsov V, Zayed H, Duliege AM. Bussel J, et al. Am J Hematol. 2018 Jul;93(7):921-930. doi: 10.1002/ajh.25125. Epub 2018 May 15. Am J Hematol. 2018. PMID: 29696684 Free PMC article. Clinical Trial.
Baseline median platelet count was 16 000/muL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003). Overall responses (defined retrospectively as 1 platelet count 50 000/muL within the first 12 we …
Baseline median platelet count was 16 000/muL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fost …
Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.
Wang M, Zhang Z, Liu J, Song M, Zhang T, Chen Y, Hu H, Yang P, Li B, Song X, Pang J, Xing Y, Cao Z, Guo W, Yang H, Wang J, Yang J, Wang C. Wang M, et al. Signal Transduct Target Ther. 2022 May 13;7(1):157. doi: 10.1038/s41392-022-00959-3. Signal Transduct Target Ther. 2022. PMID: 35551173 Free PMC article.
Notably, the phosphorylation of EGFR (p-EGFR) and SYK (p-SYK) were identified as potential therapeutic targets in the progression of silicosis. To inhibit and validate these targets, we tested fostamatinib (targeting SYK) and Gefitinib (targeting EGFR), and both drugs effe …
Notably, the phosphorylation of EGFR (p-EGFR) and SYK (p-SYK) were identified as potential therapeutic targets in the progression of silicos …
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N, Ghanima W, Hill QA, Nicolson PL, Markovtsov V, Kessler C. Cooper N, et al. Platelets. 2023 Dec;34(1):2131751. doi: 10.1080/09537104.2022.2131751. Epub 2022 Nov 4. Platelets. 2023. PMID: 36331249 Free article. Review.
The aim of this narrative review is to summarize the biological properties of SYK and its involvement in disease pathways, provide an update on SYK inhibitors in the treatment of ITP, and consider other potential applications. Fostamatinib, the only licensed SYK inhibitor …
The aim of this narrative review is to summarize the biological properties of SYK and its involvement in disease pathways, provide an update …
Recent progress in ITP treatment.
Rodeghiero F. Rodeghiero F. Int J Hematol. 2023 Mar;117(3):316-330. doi: 10.1007/s12185-022-03527-1. Epub 2023 Jan 9. Int J Hematol. 2023. PMID: 36622549 Review.
In this review, the recently approved drugs avatrombopag and fostamatinib, which were not extensively covered within 2019 international recommendations for ITP, will be discussed in some detail. ...However, data on quality of life (QoL) are lacking and the rate of thromboe …
In this review, the recently approved drugs avatrombopag and fostamatinib, which were not extensively covered within 2019 internation …
Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J. Paik J. Drugs. 2021 Jun;81(8):935-943. doi: 10.1007/s40265-021-01524-y. Epub 2021 May 10. Drugs. 2021. PMID: 33970459 Review.
By inhibiting Syk activation in macrophages, fostamatinib blocks autoantibody-mediated platelet phagocytosis. In the placebo-controlled phase III FIT1 and FIT2 trials, 24 weeks of oral fostamatinib therapy increased platelet count in previously treated adults with I …
By inhibiting Syk activation in macrophages, fostamatinib blocks autoantibody-mediated platelet phagocytosis. In the placebo-controll …
Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, Tomiyama Y; R788-1301 Investigators. Kuwana M, et al. Br J Haematol. 2023 Mar;200(6):802-811. doi: 10.1111/bjh.18582. Epub 2022 Dec 5. Br J Haematol. 2023. PMID: 36470677 Clinical Trial.
We conducted a phase 3, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of fostamatinib in Japanese patients with primary ITP. Thirty-four patients were randomised to fostamatinib (n = 22) or placebo (n = 12) at 100-150 mg …
We conducted a phase 3, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of fostamatinib in …
Fostamatinib: First Global Approval.
Markham A. Markham A. Drugs. 2018 Jun;78(9):959-963. doi: 10.1007/s40265-018-0927-1. Drugs. 2018. PMID: 29869203 Review.
Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anaemia and IgA nephropathy. ...This article summarizes the milestones in the development of …
Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune th …
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A, Lee EJ, McDonald V, Bussel JB. Newland A, et al. Immunotherapy. 2018 Jan;10(1):9-25. doi: 10.2217/imt-2017-0097. Epub 2017 Oct 2. Immunotherapy. 2018. PMID: 28967793 Free article. Review.
., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic ITP. Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chroni …
., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial number of patients with chronic …
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.
Matsukane R, Suetsugu K, Hirota T, Ieiri I. Matsukane R, et al. Clin Pharmacokinet. 2022 Jul;61(7):955-972. doi: 10.1007/s40262-022-01135-0. Epub 2022 Jul 4. Clin Pharmacokinet. 2022. PMID: 35781630 Free PMC article. Review.
Fostamatinib is the first approved spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia. ...Fostamatinib is designed as a prodrug and cleavage of its active moiety R406 in the intestine. ...
Fostamatinib is the first approved spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia. ...Fostamatinib is de …
189 results